Treace Medical Concepts, Inc.
NASDAQ:TMCIMedical - Devices
+$0.08 today
- Market cap
- $296.98M
- Beta
- 1.41
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.95
Volume 0.18M
Average 0.73M
TMCI Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Treace Medical Concepts, Inc.NASDAQ: TMCI
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $899K fell 63.5% year over year, behind the +1.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 68.8% from the prior quarter. Over 3 fiscal years it compounded at +70.1% a year.
Context
- Depreciation & amortization amounted to 4.9% of revenue in FY2025, up 0.9 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -63.5% toward the trailing-twelve-month pace of +1.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 10.5M USD
- Year-over-year change
- +24.7%
- 4-year CAGR
- +97.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.5M | +24.7% |
| FY2024 | 2024-12-31 | 8.42M | +57.3% |
| FY2023 | 2023-12-31 | 5.35M | +150.9% |
| FY2022 | 2022-12-31 | 2.13M | +211.4% |
| FY2021 | 2021-12-31 | 685K | — |
Depreciation & Amortization vs competitors
How TMCI compares with its peers on the latest reported figures
- TMCI's LTM Mar 2026 depreciation & amortization of $9.13M is the 4th highest of the 8 companies compared; the peer median is $6.78M.
- Its year-over-year change of +1.8% is the 5th highest of 8, against a peer median of +2.9%.
- Depreciation & amortization amounts to 4.4% of revenue for TMCI, versus a peer median of 3.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $46.35M | -6.6% | -5.3% | 8.0% | |
| LTM Mar 2026 | $21.79M | +14.1% | +17.5% | 9.0% | |
| LTM Mar 2026 | $9.28M | +53.3% | +32.9% | 3.1% | |
| LTM Mar 2026 | $9.13M | +1.8% | +70.1% | 4.4% | |
| LTM Mar 2026 | $6.78M | +2.9% | +16.3% | 1.2% | |
| LTM Mar 2026 | $6.29M | -60.3% | -22.5% | 7.3% | |
| LTM Mar 2026 | $3.32M | +1.7% | — | 2.6% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $1.25M | +3.0% | +39.2% | 1.3% |
| Peer median (excluding TMCI) | $6.78M | +2.9% | +16.9% | 3.1% | |
Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 94.42M | 141.84M | 187.12M | 209.36M | 212.69M |
| Cost of Revenue | 16.89M | 27.52M | 35.18M | 41.09M | 42.94M |
| Gross Profit | 77.53M | 114.32M | 151.94M | 168.26M | 169.75M |
| Gross Margin | 82.1% | 80.6% | 81.2% | 80.4% | 79.8% |
| Research & Development | 10.2M | 13.58M | 15.44M | 20.59M | 20.28M |
| Selling, General & Admin | 83.84M | 137.57M | 187.93M | 203.36M | 203.62M |
| Operating Expenses | 94.04M | 149.16M | 203.37M | 223.95M | 223.91M |
| Depreciation & Amortization | 685K | 2.13M | 5.35M | 8.42M | 10.5M |
| EBITDA | (15.81M) | (36.28M) | (39.01M) | (42.07M) | (43.18M) |
| EBITDA Margin | -16.7% | -25.6% | -20.8% | -20.1% | -20.3% |
| Operating Income | (16.51M) | (34.84M) | (51.43M) | (55.69M) | (54.15M) |
| Operating Margin | -17.5% | -24.6% | -27.5% | -26.6% | -25.5% |
| Interest Income | 18K | 1.31M | 6.73M | 4.88M | 2.78M |
| Interest Expense | 4.06M | 4.4M | 5.17M | 5.26M | 5.32M |
| Other Income / Expenses | (4.04M) | (7.97M) | 1.9M | (55K) | (4.85M) |
| Income Before Tax | (20.55M) | (42.82M) | (49.53M) | (55.74M) | (59M) |
| Pre-Tax Margin | -21.8% | -30.2% | -26.5% | -26.6% | -27.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.55M) | (42.82M) | (49.53M) | (55.74M) | (59M) |
| Net Margin | -21.8% | -30.2% | -26.5% | -26.6% | -27.7% |
| EPS (Basic) | (0.38) | (0.77) | (0.81) | (0.90) | (0.93) |
| EPS (Diluted) | (0.38) | (0.77) | (0.81) | (0.90) | (0.93) |
| Weighted Avg Shares | 54.18M | 55.28M | 60.85M | 62.11M | 63.27M |
| Weighted Avg Shares (Diluted) | 54.18M | 55.28M | 60.85M | 62.11M | 63.27M |
Treace Medical Concepts, Inc.
NASDAQ:TMCI
Intrinsic Alpha fair value
Locked
Current Price
$4.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.